C92.11 Chronic myeloid leukemia, BCR/ABL-positive, in remission

Name of the Condition

• Chronic myeloid leukemia, BCR/ABL-positive, in remission

Summary

Chronic myeloid leukemia (CML) is a cancer of the bone marrow and blood, marked by the overproduction of abnormal white blood cells. The BCR/ABL-positive subtype is defined by the presence of the BCR/ABL fusion gene, a key genetic abnormality driving the disease. When in remission, the disease is controlled, with no detectable signs of active cancer, though ongoing monitoring is essential.

Causes

CML is primarily caused by a genetic mutation resulting in the BCR/ABL fusion gene. This gene produces an abnormal tyrosine kinase protein that disrupts normal cell regulation, leading to uncontrolled proliferation of myeloid cells. The mutation occurs spontaneously in most cases and is not inherited.

Risk Factors

• Age: Most common in adults, with incidence increasing after age 60.
• Gender: Slightly more prevalent in males.
• Exposure to high levels of ionizing radiation.
• No significant family history or inherited genetic predisposition.

Symptoms

• Fatigue or weakness
• Unexplained weight loss or fever
• Night sweats
• Enlarged spleen or abdominal discomfort
• Frequent infections
• Anemia or easy bruising/bleeding

Diagnosis

Diagnosis involves blood tests to detect abnormal white blood cell counts, followed by a bone marrow biopsy to confirm the presence of the BCR/ABL fusion gene. Cytogenetic or molecular testing may be used to assess remission status, with no detectable disease activity in this state.

Treatment Options

• Tyrosine kinase inhibitors (TKIs) to target the BCR/ABL protein.
• Regular monitoring to maintain remission.
• Possible discontinuation of TKIs in select patients with sustained molecular remission.

Prognosis and Follow-Up

With effective treatment, many patients achieve long-term remission. Follow-up includes regular blood tests and molecular monitoring to detect any recurrence. Prognosis is generally favorable when remission is maintained, though lifelong surveillance is recommended.

Complications

• Risk of disease recurrence if remission is lost.
• Potential side effects from long-term TKI therapy.
• Rare progression to accelerated or blast phase if remission is not sustained.

Lifestyle & Prevention

• Avoid exposure to ionizing radiation.
• Maintain a healthy lifestyle to support overall well-being.
• Follow prescribed treatment and monitoring schedules strictly.

When to Seek Professional Help

Seek medical attention if symptoms such as persistent fatigue, unexplained weight loss, or signs of infection occur, as these may indicate a loss of remission or disease progression.

Tips for Medical Coders

Document the presence of remission status clearly in clinical records. Ensure the BCR/ABL-positive subtype and remission status are accurately reflected to support code assignment. Verify that documentation aligns with the clinical definition of remission for this condition.